Previous close | 262.75 |
Open | 264.21 |
Bid | 268.91 x 100 |
Ask | 269.07 x 100 |
Day's range | 260.68 - 269.38 |
52-week range | 211.71 - 329.72 |
Volume | |
Avg. volume | 2,926,216 |
Market cap | 144.248B |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | 21.55 |
EPS (TTM) | 12.48 |
Earnings date | 02 May 2024 |
Forward dividend & yield | 9.00 (3.43%) |
Ex-dividend date | 16 May 2024 |
1y target est | 306.20 |
Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.